Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-?1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
相关临床试验
23
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
11
47.8%
已完成
6
26.1%
招募中
4
17.4%
终止
2
8.7%
暂无批准数据
- Pliant Therapeutics' FORTIFY Phase 1b trial of PLN-101095 in ICI-refractory solid tumors is enrolling ahead of schedule, with interim data expected in 2027. - Updated Phase 1 biomarker data presented at AACR showed coordinated T-cell reactivation cascade, including increases in IFN-γ, CXCL9, and granzyme-B in all responders. - The company appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, adding deep oncology drug development and commercialization expertise. - Pliant reported a reduced net loss of $22.4 million for Q2 2026 and holds $159.6 million in cash, sufficient to fund operations into the second half of 2028.
- Tarsus Pharmaceuticals has appointed David E. I. Pyott, former Chairman and CEO of Allergan, to its Board of Directors to support the company's growth strategy. - Pyott transformed Allergan from a $1 billion eye care business into a global specialty pharmaceutical leader generating over $7 billion in revenue during his 17-year tenure. - The appointment comes as Tarsus advances its eye care portfolio, including FDA-approved XDEMVY for Demodex blepharitis and Phase 2 programs for ocular rosacea and Lyme disease prevention. - Pyott's extensive experience in eye care innovation and global commercial execution is expected to support Tarsus's pipeline development and market expansion efforts.
- Pliant Therapeutics completed enrollment of its Phase 1 trial for PLN-101095, an oral dual integrin inhibitor designed to overcome immune checkpoint resistance in solid tumors. - Interim data showed PLN-101095 achieved a 50% objective response rate in the third dose cohort and was well tolerated across all tested doses. - The company expects to report complete trial data including results from the two highest dose cohorts by the end of 2025. - Pliant reduced operating expenses by 54% year-over-year following discontinuation of the BEACON-IPF trial and strategic workforce restructuring.
- Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights. - The acquisition represents the latest example of investment firms targeting struggling biotech "zombies" worth less than their cash reserves for liquidation rather than strategic repositioning. - Elevation's lead cancer drug disappointed in clinical testing, forcing the company to shelve its program, lay off most staff, and trade below $1 per share for nearly a year. - The deal follows Tang Capital's previous acquisitions of struggling biotechs including Allakos, Jounce Therapeutics, and Kronos Bio through its liquidation-focused investment strategy.
- Pliant Therapeutics has announced a 45% reduction in its workforce following the termination of its Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). - The company's stock experienced a significant decline after revealing disappointing efficacy data from the bexotegrast (PLN-74809) trial, which failed to meet key endpoints. - Pliant is implementing a strategic reorganization to extend its cash runway, focusing resources on its remaining pipeline candidates while discontinuing the IPF program.
• Interim data from a Phase 1 trial showed 50% objective response rate in patients receiving PLN-101095 with pembrolizumab at the highest dose tested (1000 mg BID), with confirmed partial responses across multiple tumor types including NSCLC, melanoma, and cholangiocarcinoma. • The integrin αvβ8 and αvβ1 inhibitor PLN-101095 was generally well tolerated across all doses, with rash (33.3%), fatigue (22.2%), and squamous cell carcinoma/keratoacanthoma (22.2%) being the most common treatment-emergent adverse events. • The novel combination targets the TGF-β pathway to potentially overcome immune checkpoint inhibitor resistance by increasing immune cell infiltration into the tumor microenvironment, offering hope for patients with limited treatment options.
• Pliant Therapeutics has announced the termination of their Phase 2b clinical trial evaluating an investigational therapy for idiopathic pulmonary fibrosis, citing strategic portfolio decisions. • The decision impacts the development program for their lead compound in IPF treatment, marking a significant shift in the company's therapeutic pipeline strategy. • This development adds to the challenges in the IPF therapeutic landscape, where there remains a high unmet need for effective treatment options.
• Pliant Therapeutics has suspended enrollment and dosing in their Phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis following safety monitoring board recommendations. • RBC Capital Markets responds by downgrading Pliant Therapeutics stock from Outperform to Sector Perform, dramatically reducing price target from $45 to $4. • The trial suspension could either lead to protocol modifications in consultation with FDA or potentially signal serious safety concerns that might end the program entirely.
- Pliant Therapeutics has temporarily suspended enrollment and dosing in its Phase IIb/III BEACON-IPF trial of Bexotegrast following recommendations from the independent Data Safety Monitoring Board. - The clinical trial pause impacts the study's original timeline, which aimed to complete Phase IIb enrollment of 360 idiopathic pulmonary fibrosis patients by Q1 2025. - The company's stock experienced significant decline, dropping 34.81% in regular trading and an additional 58% in after-hours trading to $3.27.
- The advanced liver cancer market is projected to grow from $2.31 billion in 2024 to $11.13 billion by 2035, exhibiting a CAGR of 15.38%, according to IMARC Group research. - Advancements in early detection technologies, including multi-modal MRI, contrast-enhanced ultrasound, and liquid biopsy, are significantly improving diagnosis and expanding treatment options for patients. - Novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments, are transforming patient outcomes, with drugs like Namodenoson showing promising results in clinical trials.
